Overview

Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate the efficacy of a multi factorial preventive scheme of action (including fluvastatin and valsartan) to reduce the overall risk level in patients with metabolic syndrome.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Novartis
Treatments:
Fluvastatin
Hydrochlorothiazide
Valsartan
Criteria
Inclusion Criteria:

- Age between 40 - 65 years

- Diagnosed metabolic syndrome

- Risk of cardiovascular death ≥ 5% (according to SCORE)

- Written informed consent

Exclusion Criteria:

- Women not in menopause or not using efficient contraception

- Known hypersensitivity to study drugs

- History of ischemic heart disease